Molecular subtypes in BC can be identified by the immunohistochemistry analysis of four key markers in the clinical routine: estrogen receptors (ER), progesterone receptors (PR), type 2 human epidermal growth factor receptor (HER2), and the cellular proliferation index Ki-67. Here, ESR1 is linked to breast cancer.